Skip to main content

Table 1 Ongoing clinical trials of tyrosine kinase inhibitors for lung cancer in China

From: Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

Agents Location(s) Identifier Phase PI in China Indication Intervention/content Status in China
Targeting EGFR pathway
 Afatinib I NCT01953913 3 Yi-long Wu Without history of EGFR TKI treatment Afatinib efficacy in NSCLC with EGFR mutation(s) Recruiting
 Icotinib D NCT02714010 3 Li-kun Chen Without history of EGFR TKI treatment WBI concurrent with EGFR TKI vs EGFR TKI Recruiting
 Epitinib D NCT02590952 1 Yi-long Wu Without history of EGFR TKI treatment/developed brain lesions during TKI therapy Pharmacokinetics, safety, and tolerability in solid tumors Recruiting
 Hemay020 D NCT02467569 1 Hai-ying Wu Second-line and beyond Pharmacokinetics, safety, and tolerability in solid tumors Recruiting
Targeting T790M pathway
 Osimertinib I NCT02296125 3 Yi-long Wu First-line Osimertinib vs EGFR TKI in advanced NSCLC Active, not recruiting
 Avitinib D NCT02330367 1/2 Yi-long Wu Second-line and beyond Safety, tolerability, pharmacokinetics, and efficacy in T790M-positive advanced NSCLC Recruiting
 Alflutinib D NCT02973763 1 Yuan-kai Shi Second-line and beyond Pharmacokinetics, safety, and tolerability in NSCLC after progression on prior EGFR TKI Not yet recruiting
Targeting HER2 pathway
 Afatinib I NCT02597946 2 Cai-cun Zhou Second-line and beyond Efficacy in HER2 mutation NSCLC after chemotherapy Recruiting
 Pyrotinib D NCT02535507 2 Cai-cun Zhou Third-line and beyond Efficacy in HER2 mutation advanced NSCLC Recruiting
 Allitinib D CTR20150258 2 Yi-long Wu Second-line and beyond Safety and efficacy in uncommon EGFR mutant or HER2 mutation/amplification NSCLC Recruiting
Targeting ALK pathway
 Alectinib I NCT02838420 3 Cai-cun Zhou First-line Alectinib vs crizotinib in Asian patients NSCLC Recruiting
 CT-707 D NCT02695550 1 Yuan-kai Shi Second-line and beyond Pharmacokinetics, safety, and tolerability in ALK-positive NSCLC Recruiting
 Ensartinib D NCT02959619 1 Li Zhang Without history of ALK TKI treatment except crizotinib Pharmacokinetics, safety, and tolerability in ALK-positive NSCLC Not yet recruiting
 SAF-189s D CTR20160340 1/2 Yi-long Wu Second-line and beyond Safety, tolerability, pharmacokinetics, and efficacy in ALK-positive NSCLC Recruiting
Targeting c-MET pathway
 INC280 I NCT02276027 2 Yi-long Wu Without history of c-MET TKI treatment INC280 in NSCLC with c-MET gene alteration Recruiting
 Volitinib D NCT02374645 1 Jin-ji Yang Second-line Volitinib in combination with gefitinib in EGFR-mutated, c-MET-alternated NSCLC after progress on EGFR TKI Recruiting
 Bozitinib D NCT02896231 1 Yi-long Wu Without history of c-MET/HGF inhibitor treatment Safety, tolerability, and pharmacokinetics in MET-positive advanced NSCLC Recruiting
 BPI-9016M D NCT02929290 1 Yuan-kai Shi Second-line and beyond Safety, efficacy, and pharmacokinetics in c-MET dysregulated advanced NSCLC Not yet recruiting
Targeting VEGFR pathway
 Fruquintinib D NCT02976116 2 Jian-ying Zhou First-line Fruquintinib in combination with gefitinib in non-squamous NSCLC with activating EGFR mutation Recruiting
   NCT02691299 2 Jian-ying Zhou Third-line Placebo-controlled in advanced non-squamous NSCLC Recruiting
 Apatinib D NCT02824458 3 Hong-yun Zhao First-line Gefitinib in combination with apatinib or placebo in EGFR mutation-positive advanced non-squamous NSCLC Recruiting
   NCT02332512 3 Li Zhang Third/fourth-line Apatinib in advanced non-squamous NSCLC harboring wild-type EGFR Recruiting
 Famitinib D NCT02766140 3 Cai-cun Zhou Second-line Famitinib plus docetaxel compared to placebo plus docetaxel in advanced or metastatic or recurrent non-squamous NSCLC Recruiting
 Endostar D NCT02001168 3 Zuo-liang Pang Postoperative adjuvant Comparison of postoperative adjuvant chemotherapy with/without Rh-endostat in phase Ib NSCLC Active, not recruiting
 Anlotinib D NCT03059797 2 Ying Cheng Third-line and beyond Compare the efficacy and safety of anlotinib vs placebo in SCLC Recruiting
Targeting RET pathway
 Apatinib D NCT02540824 2 Cai-cun Zhou Second-line and beyond Efficacy and safety of apatinib as a single agent in RET fusion gene-positive NSCLC Recruiting
   NCT02780778 2/3 Zhan-yu Pan Second-line Apatinib plus docetaxel in advanced non-squamous NSCLC Recruiting
Targeting ROS-1 pathway
 Crizotinib I NCT01945021 2 Jin-ji Yang First-line or no more than third-line treatment Safety and efficacy of crizotinib in East Asian patients with ROS1-positive, ALK-negative advanced NSCLC Active, not recruiting
 Apatinib D NCT03164694 2 Si-yu Wang First-line Apatinib plus chemotherapy vs chemotherapy in ROS1 gene rearrangement advanced NSCLC Recruiting
Targeting BRAF pathway
 BGB-283 D CTR20150575 1 Lin-Shen Second-line and beyond Pharmacokinetics, safety, and tolerability in advanced solid tumor Recruiting
  1. EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, HER2 human epidermal growth factor receptor-2, MET mesenchymal epithelial transition, VEGFR vascular endothelial growth factor receptor, PI principal investigator, I international, D domestic